GLP-1 & Weight Loss
Written by Dr. Lori Martin, M.D., Medical Director, THRIVE 4 Peak Performance. Dr. Martin specializes in performance medicine, metabolic health, and physician-supervised weight loss.
Related reading: GLP-1 Weight Loss: What to Expect | Semaglutide vs. Tirzepatide | What Is Peptide Therapy?
GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and their compounded equivalents — have transformed the landscape of physician-supervised weight loss. But anyone who has been on one of these medications for more than a few weeks knows that the journey isn't always smooth. Nausea, fatigue, loss of appetite so severe it affects nutritional intake, and gradual muscle loss are real, documented side effects that cause many patients to reduce their dose, skip injections, or discontinue treatment entirely before reaching their goals.
At THRIVE 4 Peak Performance in Alpharetta, we've built a supportive care protocol specifically designed for GLP-1 patients. It combines physician-supervised IV therapy with targeted peptide therapy to address the most common side effects, protect lean muscle mass, and help patients stay on track — and actually feel good — throughout their weight loss journey.
GLP-1 receptor agonists work in part by slowing gastric emptying and suppressing appetite signaling in the brain. These are the mechanisms that drive weight loss — but they're also directly responsible for the most common complaints. When gastric emptying slows, food stays in the stomach longer, which causes nausea and bloating. When appetite is suppressed more aggressively than expected, patients may eat too little — not just in terms of calories, but in critical micronutrients, protein, and hydration.
The problem compounds over time. Rapid weight loss without adequate protein intake and resistance training leads to significant lean muscle loss — a phenomenon called sarcopenic obesity, where body fat percentage actually increases even as the scale drops. Patients also frequently experience B vitamin and electrolyte depletion because reduced food volume means reduced dietary intake of these essentials. The result is a cluster of symptoms — fatigue, brain fog, weakness, hair thinning, irritability — that have little to do with the medication itself and everything to do with nutritional deficiency.
The good news: these side effects are addressable. And addressing them effectively keeps patients on therapy long enough to achieve and sustain meaningful results.
The most frequently reported side effect, particularly in the first 4–12 weeks or after dose escalations. Slowed gastric motility keeps stomach contents present longer than normal. IV hydration with an antiemetic adjunct (when appropriate) and electrolyte replenishment can significantly reduce nausea severity and duration, allowing patients to stay at their therapeutic dose rather than retreating to a lower one.
Reduced caloric intake combined with lower micronutrient consumption creates an energy deficit that goes beyond simple calorie restriction. B12, B-complex, magnesium, and zinc are frequently depleted in GLP-1 patients — and oral supplements are poorly absorbed when GI motility is impaired. IV delivery bypasses the gut entirely, restoring functional nutrient levels within hours rather than days.
Emerging clinical data suggests that 25–40% of weight lost on GLP-1 therapy can come from lean mass rather than fat — a significant concern for long-term metabolic health. Certain peptides, particularly BPC-157 and to a lesser extent CJC-1295/Ipamorelin, support muscle tissue preservation and anabolic signaling during periods of caloric restriction. Combined with appropriate protein targets, these peptides help shift the composition of weight loss toward fat preferentially.
Reduced fluid and food intake, combined with GI symptoms, makes dehydration a persistent risk on GLP-1 therapy. Dehydration worsens fatigue, cognitive performance, and nausea — creating a feedback loop that makes side effects feel worse. IV hydration with a balanced electrolyte solution breaks this cycle quickly and reliably in ways that oral rehydration cannot match when nausea is a factor.
Our IV therapy program is physician-supervised and tailored to the specific needs of patients on GLP-1 medications. The most commonly used formulations for GLP-1 support include:
A baseline IV hydration bag with sodium, potassium, magnesium, and calcium replenishment. This is the starting point for patients experiencing nausea, fatigue, or brain fog on GLP-1 therapy. Many patients notice a meaningful improvement in energy and symptom severity within a few hours of treatment — and the relief carries forward for several days to a week after each infusion.
The Myers' Cocktail — combining magnesium, calcium, B-complex, B12, and Vitamin C — addresses the micronutrient depletion that underlies GLP-1-associated fatigue. The magnesium component has documented anxiolytic and anti-nausea properties. B12 supports neurological function, mood stability, and red blood cell production. Many GLP-1 patients schedule a Myers' Cocktail within a day or two of their weekly injection to preempt the energy dip that often follows.
Caloric restriction accelerates the decline of NAD+ — a coenzyme central to mitochondrial energy production, DNA repair, and metabolic efficiency. NAD+ IV therapy directly restores cellular energy currency, supporting the mitochondrial function that keeps GLP-1 patients energized and metabolically active even as they lose weight. Many patients who add NAD+ to their GLP-1 protocol report a notable improvement in mental clarity and physical energy that persists beyond what hydration and B vitamins alone provide.
Glutathione is the body's master antioxidant, and its levels decline under caloric restriction and physiological stress. A glutathione push — often added to the end of a Myers' or hydration infusion — supports liver detoxification (important when the liver is handling significant metabolic load during active weight loss), reduces oxidative stress, and contributes to the skin quality improvements many patients prioritize during their transformation.
Peptide therapy operates on a different mechanism than IV nutrition — it works at the cellular signaling level to support tissue repair, anabolic function, and metabolic regulation. For GLP-1 patients, we most commonly use:
BPC-157 is a synthetic peptide derived from a naturally occurring gastric protein. It has well-documented effects on GI healing — making it particularly relevant for patients experiencing persistent nausea or GI irritation from GLP-1 therapy. It also supports muscle and connective tissue repair, which is meaningful when lean mass preservation is a priority during caloric restriction. Patients on BPC-157 alongside their GLP-1 medication frequently report faster resolution of GI symptoms and improved recovery from exercise.
This peptide combination stimulates the pituitary gland's natural growth hormone release, promoting lean muscle preservation and fat metabolism. During periods of significant caloric restriction — as is common on GLP-1 therapy — growth hormone signaling helps the body preferentially burn fat rather than muscle. This directly addresses one of the most clinically significant concerns with long-term GLP-1 use: the risk of body composition changes that leave patients metabolically worse off than before treatment.
Every GLP-1 support visit at THRIVE begins with a brief physician check-in to assess your current side effect profile, weight loss progress, and any changes to your medication status. We use that intake to customize the day's IV formulation and determine whether any peptide adjustments are warranted.
Most visits last 45–90 minutes depending on the infusions selected. You're welcome to rest, work, or watch content during the session. Same-week and next-day scheduling is typically available at our Alpharetta clinic on Old Milton Pkwy, and many patients integrate their THRIVE support visits into their existing weekly injection routine.
Whether you're just starting GLP-1 therapy, struggling through a difficult dose escalation, or approaching your goal weight and prioritizing body composition, THRIVE's physician-led support protocol is designed to keep you feeling strong, energized, and on track throughout your journey.
IV therapy and peptide protocols tailored to your GLP-1 journey. Same-week appointments available at THRIVE 4 Peak Performance on Old Milton Pkwy, Alpharetta.
Book an Appointment Call (470) 359-6195Yes, and for many patients this is the optimal timing. A hydration and electrolyte infusion given within 12–24 hours of your injection — either just before or after — can meaningfully reduce the nausea and energy dip that often follows dose day. Your physician at THRIVE will recommend the best timing window based on your specific medication and response pattern.
No. We work with patients who are receiving GLP-1 medications from any prescriber — their primary care physician, an endocrinologist, a telehealth service, or another clinic. Our role is to provide physician-supervised supportive care that complements your existing treatment plan, not to replace it.
BPC-157 and growth hormone secretagogues like CJC-1295/Ipamorelin work through different mechanisms than GLP-1 receptor agonists and do not interact with semaglutide or tirzepatide pharmacologically. However, every patient's health history is different, and our physician will review your full medication list and health status before recommending any peptide protocol.
Most GLP-1 prescribers — including telehealth platforms — focus on the medication itself: dosing, titration, and monitoring. Very few provide structured nutritional support, IV therapy, or adjunctive peptide protocols. THRIVE fills that gap with hands-on, in-person physician care designed to optimize how you feel and perform throughout your weight loss journey.
THRIVE 4 Peak Performance is located at 3568 Old Milton Pkwy, Alpharetta, GA 30005. We serve Alpharetta, Milton, Roswell, Johns Creek, and Cumming. Call (470) 359-6195 to schedule your GLP-1 support consultation.